Skip to main
ICCM
ICCM logo

ICCM Stock Forecast & Price Target

ICCM Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Icecure Medical Ltd reported a significant 102% growth in total revenue for the third quarter of 2024, reaching $0.7 million, which aligns with projections and reflects robust demand for its cryoablation products. Sales of ProSense systems and disposable probes saw a 36% increase to $2.3 million for the first nine months of 2024, driven by expansion in key markets across Europe, the U.S., Japan, and Asia, indicating a strong international presence. Furthermore, the recent FDA marketing authorization for the XSense system underscores the viability of Icecure's cryoablation technology, potentially bolstering its market position and paving the way for further growth pending upcoming regulatory decisions.

Bears say

Icecure Medical Ltd faces significant challenges that contribute to a negative outlook on its stock, primarily due to the risk of its cryoablation systems failing to achieve commercial success in a competitive market. The company confronts potential setbacks, including failures in clinical trials and the possibility of not obtaining necessary regulatory approvals in the U.S., which could further hinder its market penetration. Additionally, concerns regarding dilution risk diminish investor confidence and complicate the company's financial stability and growth prospects.

ICCM has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Icecure Medical Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Icecure Medical Ltd (ICCM) Forecast

Analysts have given ICCM a Strong Buy based on their latest research and market trends.

According to 4 analysts, ICCM has a Strong Buy consensus rating as of Jul 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.51, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.51, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Icecure Medical Ltd (ICCM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.